Theravance Biopharma (TBPH) SVP Rhonda Farnum Sells Shares

What Happened Rhonda Farnum, Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma, sold a total of 13,314 shares in open-market transactions on September 15, 2026. The trades were reported at a weighted average price of $17.03 per share for total gross proceeds of approximately $226,794. These were outright sales (code S) and therefore represent dispositions of existing holdings rather than purchases.

Key Details

• Transaction date: 2026-09-15 (reported on Form 4 filed 2026-09-17). Filing appears timely under Section 16 rules.
• Trades: three disposals — 3,329 shares ($56,707), 3,328 shares ($56,690), and 6,657 shares ($113,397); weighted average price reported $17.03.
• Footnote: transactions executed in multiple trades at prices from $17.02 to $17.06; weighted average shown. The reporting person offers to provide full trade-by-trade details upon request (Footnote F1).
• Plan/authorization: sales were executed under a pre-arranged 10b5-1 trading plan dated 09/03/2025 (not a discretionary sale on the reporting date).
• Shares owned after transaction: not stated in the excerpt of the filing provided.

Context Sales made under a 10b5-1 plan are pre-scheduled arrangements that can limit the extent to which a sale signals the insider’s current view of the company. For retail investors, purchases are generally more informative about insider sentiment; routine, pre-arranged sales are common for executives managing diversification or liquidity needs and do not by themselves indicate a change in company outlook.